The assessment of all severe aortic stenosis patients at intermediate risk of the SURTAVI was finally completed, confirming inferiority against the traditional surgical replacement (SAVR) in hard points such as all-cause mortality and disabling stroke. 

The aim of this study was to report SURTAVI 2-year outcomes (Surgical Replacement and Transcatheter Aortic Valve Implantation) and confirm this year’s interim results.

The SURTAVI randomized 1660 patients. After 2 years, there was a primary end point rate of 12.7% in the TAVR group and 12.6% in the SAVR group. At one year, the interim analysis outcomes had been 12.6% vs 14% respectively.

Conclusion

TAVR results were non inferior to SAVR in terms of death and disabling stroke in intermediate risk patients. These results confirm the interim analysis presented last year, follow-up has been planned to 10 years to find out potential late adverse events such as valve thickening, prosthesis dysfunction, etc. 

Original Title: Complete 2-Year Results Confirm Bayesian Analysis of the SURTAVI Trial.

Reference: Nicolas M. Van Mieghem et al. J Am Coll Cardiol Intv 2020;13:323–31.

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.